M&T Bank Corp Makes New $4.10 Million Investment in Compass Therapeutics, Inc. $CMPX

Key Points

• M&T Bank Corp initiated a new position in Compass Therapeutics in Q4, acquiring 764,229 shares worth approximately $4.10 million, or about 0.43% of the company.
• Analysts' views are mixed but generally positive: the consensus rating is "Moderate Buy" with an average target of $13.11, ranging from sell to strong-buy recommendations.
• Compass is a clinical-stage immuno-oncology biotech (market cap ~$902.8M) trading near $5, with lead programs CTX-471 and DSP107 and a 52-week range of $1.66–$6.88.

M&T Bank Corp bought a new position in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 764,229 shares of the company's stock, valued at approximately $4,104,000. M&T Bank Corp owned about 0.43% of Compass Therapeutics at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Russell Investments Group Ltd. increased its position in Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company's stock worth $27,000 after purchasing an additional 7,592 shares in the last quarter. Creative Planning bought a new position in Compass Therapeutics in the 2nd quarter valued at approximately $30,000. Flagship Harbor Advisors LLC acquired a new stake in Compass Therapeutics in the fourth quarter valued at approximately $32,000. Strs Ohio acquired a new stake in Compass Therapeutics in the first quarter valued at approximately $34,000. Finally, Apollon Wealth Management LLC bought a new stake in shares of Compass Therapeutics during the third quarter worth $35,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CMPX has been the subject of several research analyst reports. William Blair reiterated an "outperform" rating on shares of Compass Therapeutics in a report on Thursday, March 5th. Weiss Ratings reissued a "sell (d-)" rating on shares of Compass Therapeutics in a report on Monday, April 20th. Jefferies Financial Group restated a "buy" rating and set a $9.00 price objective on shares of Compass Therapeutics in a research report on Thursday, March 5th. D. Boral Capital reiterated a "buy" rating and issued a $30.00 target price on shares of Compass Therapeutics in a research report on Tuesday, January 6th. Finally, Canaccord Genuity Group set a $13.00 target price on Compass Therapeutics in a research report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $13.11.

Compass Therapeutics Stock Performance

Shares of NASDAQ CMPX opened at $5.01 on Monday. The firm has a 50 day moving average price of $5.55 and a two-hundred day moving average price of $5.30. The stock has a market cap of $902.79 million, a P/E ratio of -11.66 and a beta of 1.49. Compass Therapeutics, Inc. has a 52-week low of $1.66 and a 52-week high of $6.88.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. Analysts predict that Compass Therapeutics, Inc. will post -0.41 earnings per share for the current fiscal year.

Compass Therapeutics Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.